Jayne E. Murray
Kensington, NSW, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
The PLK4 inhibitor RP-1664 demonstrates potent single-agent efficacy in neuroblastoma models through a dual mechanism of sensitivity.
Journal: Research square
Published: August 06, 2025
The PLK4 inhibitor RP-1664 demonstrates potent efficacy in neuroblastoma preclinical models through a dual mechanism of sensitivity.
Journal: Nature communications
Published: July 06, 2025
Arginine depletion potentiates standard-of-care chemo-immunotherapy in preclinical models of high-risk neuroblastoma.
Journal: Journal of experimental & clinical cancer research : CR
Published: June 25, 2025
The cell-permeable iron chelator M606 inhibits MYCN-driven neuroblastoma via an E2F3-mediated response.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: June 02, 2025
Copper chelation redirects neutrophil function to enhance anti-GD2 antibody therapy in neuroblastoma.
Journal: Nature communications
Published: February 19, 2024
Golgi-localized Ring Finger Protein 121 is necessary for MYCN-driven neuroblastoma tumorigenesis.
Journal: Communications biology
Published: July 12, 2023
The transcriptional co-repressor Runx1t1 is essential for MYCN-driven neuroblastoma tumorigenesis.
Journal: Nature communications
Published: April 05, 2023
Inflammatory response to retrotransposons drives tumor drug resistance that can be prevented by reverse transcriptase inhibitors.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: November 30, 2022
Inhibition of mitochondrial translocase SLC25A5 and histone deacetylation is an effective combination therapy in neuroblastoma.
Journal: International journal of cancer
Published: February 16, 2022
A Primer for Assessing the Pathology in Mouse Models of Neuroblastoma.
Journal: Current protocols
Published: November 26, 2021
Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 30, 2020
Last Updated: 09/26/2026